By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring.
SmithKline Beecham Corporation v. Barr Pharmaceuticals Inc. et al.
1:08-cv-00112; filed February 25, 2008 in the District Court of Delaware
Infringement of U.S. Patent Nos. 5,565,467 ("Androstenone Derivative," issued October 15, 1996), 5,846,976 (same title, issued December 8, 1998), and 5,998,427 ("Androstenones," issued December 7, 1999) following a paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of GSK's Avodart® (dutasteride, used to treat symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate). View the complaint here.
Astellas US LLC et al. v. Anazaohealth Corporation et al.
2:08-cv-01083; filed February 15, 2008 in the Western District of California
Infringement of U.S. Patent Nos. 5,731,296 ("Selective Vasodilation by Continuous Adenosine Infusion," issued March 24, 1998) and 5,070,877 ("Novel Method of Myocardial Imaging," issued December 10, 1991), both licensed to Astellas, based on defendants' alleged marketing, through its sales agents, of its generic version of Astellas' Adenoscan® product (adenosine injection, used as a diagnostic for myocardial reperfusion injury) for use in an infringing manner. View the complaint here.
Comments